Description: BenevolentAI société anonyme operates as a clinical-stage AI-enabled drug discovery company. The company's BenevolentAI platform powers a pipeline of approximately 20 drug programs. BenevolentAI société anonyme was formerly known as BenevolentAI Limited and changed its name to BenevolentAI société anonyme on April 22, 2022. The company is headquartered in London, United Kingdom.
Home Page: www.benevolent.com
4-8 Maple Street
London,
W1T 5HD
United Kingdom
Phone:
44 20 3781 9360
Officers
| Name | Title |
|---|---|
| Ms. Joanna Shields OBE | CEO & Exec. Director |
| Dr. Ivan Griffin Ph.D. | Co-Founder & COO |
| Dr. Anne Phelan | Chief Scientific Officer & Site Head for the Benevolent Cambridge Laboratories |
| Mr. Nicholas P. Keher | Chief Financial Officer |
| Mr. Daniel Neil | Chief Technology Officer |
| Ms. Fleur Wood | VP of Investor Relations |
| Mr. Will Scrimshaw | Gen. Counsel |
| Ms. Rajin Kang | VP of Communications |
| Ms. Anna Fullerton-Batten | Chief People Officer |
| Mr. Mark Davies | Sr. VP of Informatics & Data |
Exchange: AS
Country: NL
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 61.5013 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 350 |